Experimental cancer drug TNG908 tested in patients with rare gene deletion

NCT ID NCT05275478

Terminated Disease control Sponsor: Tango Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental oral drug called TNG908 in people with advanced solid tumors that have lost a gene called MTAP. The goal was to see if the drug is safe and can shrink tumors. The study was planned for up to 192 participants but was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TNG908 (an oral PRMT5 inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for patients with certain hard-to-treat solid tumors that have a specific genetic deletion.
What could go wrong: This was a very early (Phase 1/2) study that was terminated, so results are limited. The drug may not prove effective or safe in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma glioblastoma mesothelioma neurofibrosarcoma sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED SOLID TUMOR

Contacts and locations

Locations

Carle Cancer Center

Urbana, Illinois, 61801, United States
Centre Léon Bérard

Lyon, 69373, France
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
EDOG Institut de Cancerologie de l'Ouest

Saint-Herblain, 44805, France
Florida Cancer Specialists & Research Institute

Lake Mary, Florida, 32746, United States
Grand Valley Oncology

Grand Junction, Colorado, 81505, United States
Institut Bergonié

Bordeaux, 33000, France
Institut Oncopole Claudius Regaud

Toulouse, 31059, France
Institute Gustav Roussy

Villejuif, 94805, France
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10022, United States
NEXT Oncology

Fairfax, Virginia, 22031, United States
NYU Langone Health

New York, New York, 10016, United States
Northwestern University

Chicago, Illinois, 60611, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States
Sarah Cannon Tennessee Oncology

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of California Los Angeles

Los Angeles, California, 90095, United States
University of California San Francisco

San Francisco, California, 94143, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.